Bicara Therapeutics Inc
For the period ended Sep 30, 2024. Filed Nov 12, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2024 · Filed Nov 12, 2024
BCAX$10.18+2.0%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Stockholders’ Equity
CONDENSED CONSOLIDATED STATEMENTS OF REDEEMABLE CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS’ EQUITY (DEFICIT)
(Unaudited, in thousands except shares)
| Seed Series Redeemable Convertible Preferred Stock · Series B Redeemable Convertible Preferred Stock · Common Equity · Additional Paid in Capital · Accumulated Deficit · Total Stockholders Deficit | ||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Shares · Amount · Shares · Amount · Shares · Amount | ||||||||||||||||||
| December 31, 2022 | 81,790,144 | $81,525 | — | $— | 504,544 | $2 | $2,231 | $(101,036) | $(98,803) | |||||||||
| Issuance of Series B redeemable convertible preferred stock, net of offering cost, expenses and discount | — | — | 37,073,162 | 37,185 | — | — | — | — | — | |||||||||
| Issuance of common stock upon exercise of stock options | — | — | — | — | 10,428 | — | 43 | — | 43 | |||||||||
| Stock-based compensation | — | — | — | — | — | — | 264 | — | 264 | |||||||||
| Net loss | — | — | — | — | — | — | — | (7,412) | (7,412) | |||||||||
| March 31, 2023 | 81,790,144 | 81,525 | 37,073,162 | 37,185 | 514,972 | 2 | 2,538 | (108,448) | (105,908) | |||||||||
| Issuance of common stock upon exercise of stock options | — | — | — | — | 6,739 | — | 27 | — | 27 | |||||||||
| Vesting of restricted common stock | — | — | — | — | 54,035 | — | — | — | — | |||||||||
| Stock-based compensation | — | — | — | — | — | — | 352 | — | 352 | |||||||||
| Net loss | — | — | — | — | — | — | — | (9,288) | (9,288) | |||||||||
| June 30, 2023 | 81,790,144 | 81,525 | 37,073,162 | 37,185 | 575,746 | 2 | 2,917 | (117,736) | (114,817) | |||||||||
| Issuance of Series B redeemable convertible preferred stock, net of offering cost, expenses and discount | — | — | 39,024,386 | 39,817 | — | — | — | — | — | |||||||||
| Settlement of Series B preferred stock tranche rights liability, upon issuance of milestone shares | — | — | — | 8,001 | — | — | — | — | — | |||||||||
| Issuance of common stock upon exercise of stock options | — | — | — | — | 4,229 | — | 32 | — | 32 | |||||||||
| Stock-based compensation | — | — | — | — | — | — | 519 | — | 519 | |||||||||
| Net loss | — | — | — | — | — | — | — | (22,845) | (22,845) | |||||||||
| September 30, 2023 | 81,790,144 | $81,525 | 76,097,548 | $85,003 | 579,975 | $2 | $3,468 | $(140,581) | $(137,111) | |||||||||
CONDENSED CONSOLIDATED STATEMENTS OF REDEEMABLE CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS’ EQUITY (DEFICIT)
(Unaudited, in thousands except shares)
| Seed Series Redeemable Convertible Preferred Stock · Series B Redeemable Convertible Preferred Stock · Series C Redeemable Convertible Preferred Stock · Common Equity · Additional Paid in Capital · Accumulated Deficit · Total Stockholders Equity (Deficit) | ||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Shares · Amount · Shares · Amount · Shares · Amount · Shares · Amount | ||||||||||||||||||
| December 31, 2023 | 81,790,144 | $81,525 | 105,595,101 | $121,148 | 119,599,872 | $164,604 | 640,386 | $2 | $4,250 | $(153,021) | $(148,769) | |||||||
| Issuance of common stock upon exercise of stock options | — | — | — | — | — | — | — | — | 50 | — | 50 | |||||||
| Stock-based compensation | — | — | — | — | — | — | — | — | 1,147 | — | 1,147 | |||||||
| Net loss | — | — | — | — | — | — | — | — | (12,508) | (12,508) | ||||||||
| March 31, 2024 | 81,790,144 | 81,525 | 105,595,101 | 121,148 | 119,599,872 | 164,604 | 640,386 | 2 | 5,447 | (165,529) | (160,080) | |||||||
| Issuance of common stock upon exercise of stock options | — | — | — | — | — | — | 349,962 | 1,315 | — | 1,315 | ||||||||
| Vesting of restricted common stock | — | — | — | — | — | — | 33,193 | — | — | — | ||||||||
| Stock-based compensation | — | — | — | — | — | — | — | — | 1,038 | — | 1,038 | |||||||
| Net loss | — | — | — | — | — | — | — | — | — | (17,049) | (17,049) | |||||||
| June 30, 2024 | 81,790,144 | 81,525 | 105,595,101 | 121,148 | 119,599,872 | 164,604 | 1,023,541 | 2 | 7,800 | (182,578) | (174,776) | |||||||
| Issuance of common stock, net of offering cost, expenses and discount | — | — | — | — | — | — | 20,125,000 | 2 | 332,427 | — | 332,429 | |||||||
| Conversion of convertible preferred stock into common stock upon initial public offering | (81,790,144) | (81,525) | (105,595,101) | (121,148) | (119,599,872) | (164,604) | 33,210,876 | 3 | 367,150 | — | 367,153 | |||||||
| Issuance of common stock upon exercise of stock options | — | — | — | — | — | — | 43,232 | — | 199 | — | 199 | |||||||
| Vesting of restricted common stock | — | — | — | — | — | — | 7,059 | — | — | — | — | |||||||
| Stock-based compensation | — | — | — | — | — | — | — | — | 2,031 | — | 2,031 | |||||||
| Net loss | — | — | — | — | — | — | — | — | — | (17,481) | (17,481) | |||||||
| September 30, 2024 | – | $– | – | $– | – | $– | 54,409,708 | $7 | $709,607 | $(200,059) | $509,555 | |||||||
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.